Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that is characterised by raised blood glucose levels due to resistance to the action of insulin. T2DM represents a large clinical burden; approximately 2.9 million people were diagnosed with T2DM in 2013 in the UK, 1 and treating T2DM and its complications is estimated to cost £12 billion annually. 2 Many T2DM patients' glycaemic control gradually deteriorates over time, while others do not reach their glycaemic control targets at all. For a proportion of patients, glycaemic targets are not met despite treatment with insulin, and hence therapies as add-on to insulin are required. Saxagliptin belongs to the dipeptidyl peptidase-4 inhibitor (DPP4i) class, and acts by inhibiting the DPP4 enzyme in order to prolong incretin hormone influence on enhancing blood glucose levels. Saxagliptin at 5 mg once daily is licensed as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Introduction
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that is characterised by raised blood glucose levels due to resistance to the action of insulin. T2DM represents a large clinical burden; approximately 2.9 million people were diagnosed with T2DM in 2013 in the UK, 1 and treating T2DM and its complications is estimated to cost £12 billion annually. 2 Many T2DM patients' glycaemic control gradually deteriorates over time, while others do not reach their glycaemic control targets at all. For a proportion of patients, glycaemic targets are not met despite treatment with insulin, and hence therapies as add-on to insulin are required. Saxagliptin belongs to the dipeptidyl peptidase-4 inhibitor (DPP4i) class, and acts by inhibiting the DPP4 enzyme in order to prolong incretin hormone influence on enhancing blood glucose levels. Saxagliptin at 5 mg once daily is licensed as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
-Saxagliptin is also licensed at a lower dose (2.5 mg once daily) for the treatment of T2DM patients with moderate or severe renal impairment as a result of supportive clinical evidence in this patient population. Other therapies used as an add-on to insulin in clinical practice include the glucagon-like peptide 1 (GLP-1) analogues, lixisenatide and exenatide twice-daily. The assessment of cost-effectiveness presented below formed the basis of a submission to the Scottish Medicines Consortium (SMC) for saxagliptin in the indication described above.
Objectives
To assess the cost-effectiveness of saxagliptin compared to the GLP-1 analogues, exenatide twice-daily or lixisenatide, when added to insulin (±metformin) for the treatment of patients with T2DM who are inadequately controlled on insulin.
Methods

Model structure
The validated CARDIFF diabetes model was used, which is a cost-utility model using discrete event simulation.
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The model structure is shown in Figure 1 . The model utilises United Kingdom Prospective Diabetes Study (UKPDS) 68-derived risk equations to estimate long run microand macro-vascular complications, diabetes and non-diabetes mortality and time paths for risk factors such as glycated haemoglobin (HbA1c) and systolic blood pressure (SBP). 4 The model simulates a cohort of 30,000 patients over a 40-year time horizon, with a cycle length of 6 months.
Cost-effectiveness of saxagliptin compared to GLP-1 analogues as an add-on to insulin in the treatment of type 2 diabetes mellitus from a UK healthcare perspective Patients are treated with saxagliptin or one of the GLP-1 analogues (lixisenatide or exenatide twice-daily) as add-on to insulin in the first-line, with the only subsequent line of therapy being intensified insulin as the second-line treatment. Within the model, patients experience natural progression (an increase) in HbA1c, weight and SBP over time.
-Introduction of a new treatment results in a treatment effect based on the inputs described below (Table 1 ).
-Weight changes are associated with a health-related quality of life (HRQoL) impact whilst on treatment and with cardiovascular risk over time.
-Treatment switch to second-line treatment occurs when patients reach a defined HbA1c threshold -set at ≥8% in the base case. The model considers hypoglycaemic episodes associated with therapeutic interventions and also incorporates those adverse events (AEs) that are considered most common for saxagliptin (urinary tract infections [UTI], influenza) and the GLP-1 analogues (nausea, vomiting). Although a network meta-analysis (NMA) demonstrated no statistically significant differences in the odds ratios of hypoglycaemia, absolute probabilities of hypoglycaemic events were deemed relevant to include on the basis of the clinical significance of these events.
Model inputs
Clinical effectiveness estimates for the cost-effectiveness analysis were established by a systematic review and NMA of saxagliptin and other therapies used in the add-on to insulin indication in clinical practice.
-In the base case, all efficacy parameters were included:
HbA1c, weight, hypoglycaemia, SBP, total cholesterol, high density lipoprotein-cholesterol (HDL-C), AEs and discontinuation rates.
-No NMA could be performed on the SBP outcome and hence this treatment effect was informed by a pairwise analysis versus exenatide twice-daily and set to zero versus lixisenatide; this is because results for the SBP outcome for lixisenatide were not reported, although the study authors acknowledge that no significant changes occurred.
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Utilities applied within the model are based on published utility data. Key disutilities applied are described in Table 1 . Cost and resource use estimates were based on a Scottish healthcare perspective, though inputs are considered to be comparable to those that would apply in the UK setting. The economic model considered costs and resource use associated with drug acquisition, T2DM complications, hypoglycaemia and UTI adverse events. A summary of cost inputs to the economic model is provided in Table 2 . Administration or monitoring costs were not included in the model. Costs and quality-adjusted life years (QALYs) were discounted at 3.5% in the base case of the economic model. The 95% CrI's (from the network meta-analysis) were used as upper and lower limits for sensitivity analysis of the treatment effect parameters for saxagliptin and the comparators. *For each 1 unit increase in BMI a utility decrement of -0.0061 is applied in the economic model, and for a unit decrease in BMI a utility increase of 0.0061 is applied.
¥
The decrement applies for the first year of the event and all subsequent years, and is subtracted from age adjusted no complications utility. †
No estimate available -zero value assumed.
Sensitivity analyses
Scenario, univariate and probabilistic sensitivity analyses were performed to assess the impact of assumptions and uncertainty in the model.
Results
Base case
In the base case, saxagliptin was found to be cost-effective versus both lixisenatide and exenatide twice-daily (Table 3) :
-Saxagliptin was found to dominate lixisenatide, being less costly and more effective.
-Saxagliptin was both less costly and less effective than exenatide twice-daily, resulting in an incremental costeffectiveness ratio (ICER) of £121,641 in the bottom left quadrant of the cost-effectiveness plane (Q3 ICER).
Sensitivity analyses
Univariate sensitivity analysis:
-In both comparisons, the HbA1c treatment effect of the comparator had the greatest influence on incremental costs, followed by the HbA1c treatment effect of saxagliptin. 
AE cost Cost per episode Source
Severe hypoglycaemic episode £409*** Direct healthcare costs from Hammer et al. For the comparison of saxagliptin and exenatide twice-daily, this value should be interpreted as the ICER that results from evaluating exenatide twice-daily versus saxagliptin (ie. the cost associated with each additional QALY benefit provided by exenatide twice-daily).
-Assumptions regarding the weight effect of saxagliptin generated the largest range in the incremental QALYs in both comparisons. Scenario analysis:
-Saxagliptin was found to dominate lixisenatide and be costeffective against exenatide twice-daily (Q3 ICER) in 3 separate scenarios: adjusting the HbA1c switching threshold from 8% to 7.5%, setting all hypoglycaemia parameters to zero, and using an alternative modelling of weight with no convergence of weight at initiation of second-line therapy (Table 4) . Probabilistic sensitivity analysis:
-At a willingness-to-pay threshold of £20,000 per QALY the probability that saxagliptin is cost-effective compared to lixisenatide and exenatide twice-daily is 93.4% and 99.2%, respectively. 
Discussion
Saxagliptin is associated with lower incremental costs than the GLP-1 analogue comparators in the vast majority of simulations explored, largely due to the difference in drug costs. Saxagliptin remains a cost-effective treatment option for patients with inadequate glycaemic control on insulin even under changes in key assumptions related to the HbA1c switching threshold, hypoglycaemic events and weight change profiles.
The results are based on model inputs considered to be generalisable to Scotland, and are likely relevant to the UK more widely.
Conclusion
Saxagliptin represents a cost-saving option as add-on to insulin therapy for T2DM patients.
For patients who do not achieve adequate glycaemic control on insulin alone, saxagliptin as add-on to insulin was shown to be cost-effective compared to both the GLP-1 analogue comparators considered. 
